81 related articles for article (PubMed ID: 3332182)
41. Successful treatment of late graft failure following T cell depleted bone marrow transplantation.
Jackson N; Franklin IM
Br J Haematol; 1986 May; 63(1):207-9. PubMed ID: 3518785
[No Abstract] [Full Text] [Related]
42. Timing of transplant for CML patients.
Goldman JM; Gordon-Smith EC; Catovsky D; Galton D; Reid C
Blood; 1984 Oct; 64(4):945-6. PubMed ID: 6383501
[No Abstract] [Full Text] [Related]
43. Recent advances in the therapy of chronic myelogenous leukemia.
Talpaz M; Kurzrock R; Kantarjian HM; Gutterman JU
Important Adv Oncol; 1988; ():297-321. PubMed ID: 3042607
[No Abstract] [Full Text] [Related]
44. Precision Isolation of Circulating Leukemia Cells in Chronic Myelogenous Leukemia Patients Using a Novel Microfluidic Device and Its Clinical Applications.
Ouyang D; Ye N; Yang K; Wang Y; Hu L; Chao S; Toner M; Li Y
Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067399
[TBL] [Abstract][Full Text] [Related]
45. Definition of the accelerated phase of chronic myelogenous leukemia.
Kantarjian HM; Talpaz M
J Clin Oncol; 1988 Jan; 6(1):180-2. PubMed ID: 3422090
[No Abstract] [Full Text] [Related]
46. Solitary lytic bone lesion in an adult with chronic myelogenous leukemia.
NESBITT J; ROTH RE
Radiology; 1955 May; 64(5):724-6. PubMed ID: 14372113
[No Abstract] [Full Text] [Related]
47. [Preliminary note on the association of chemotherapy and radiotherapy in the treatment of chronic myeloid leukemia].
DUSTIN P; SIMON S
J Belge Radiol; 1948; 31(2):149-55. PubMed ID: 18895019
[No Abstract] [Full Text] [Related]
48. Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations.
Patel SA; Bello E; Wilks A; Gerber JM; Sadagopan N; Cerny J
Leuk Res; 2023 Nov; 134():107388. PubMed ID: 37729719
[TBL] [Abstract][Full Text] [Related]
49. Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies.
Naserian S; Leclerc M; Shamdani S; Uzan G
Front Immunol; 2020; 11():607030. PubMed ID: 33391276
[TBL] [Abstract][Full Text] [Related]
50. IFNγR signaling mediates alloreactive T-cell trafficking and GVHD.
Choi J; Ziga ED; Ritchey J; Collins L; Prior JL; Cooper ML; Piwnica-Worms D; DiPersio JF
Blood; 2012 Nov; 120(19):4093-103. PubMed ID: 22972985
[TBL] [Abstract][Full Text] [Related]
51. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.
Choi J; Ritchey J; Prior JL; Holt M; Shannon WD; Deych E; Piwnica-Worms DR; DiPersio JF
Blood; 2010 Jul; 116(1):129-39. PubMed ID: 20424188
[TBL] [Abstract][Full Text] [Related]
52. Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine.
Shaffer J; Villard J; Means TK; Alexander S; Dombkowski D; Dey BR; McAfee S; Ballen KK; Saidman S; Preffer FI; Sachs DH; Spitzer TR; Sykes M
Exp Hematol; 2007 Jul; 35(7):1140-52. PubMed ID: 17588483
[TBL] [Abstract][Full Text] [Related]
53. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia.
Orleans-Lindsay JK; Barber LD; Prentice HG; Lowdell MW
Clin Exp Immunol; 2001 Dec; 126(3):403-11. PubMed ID: 11737054
[TBL] [Abstract][Full Text] [Related]
54. Graft versus leukemia.
Butturini A; Gale RP
Immunol Res; 1992; 11(1):24-33. PubMed ID: 1602180
[No Abstract] [Full Text] [Related]
55. The role of T-cells in preventing relapse in chronic myelogenous leukemia.
Butturini A; Gale RP
Bone Marrow Transplant; 1987 Dec; 2(4):351-4. PubMed ID: 3332182
[TBL] [Abstract][Full Text] [Related]
56. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
[TBL] [Abstract][Full Text] [Related]
57. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
58. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease.
Jiang YZ; Mavroudis DA; Dermime S; Molldrem J; Hensel NF; Barrett AJ
Bone Marrow Transplant; 1997 May; 19(9):899-903. PubMed ID: 9156263
[TBL] [Abstract][Full Text] [Related]
59. Graft-versus-leukemia in chronic lymphocytic leukemia.
Ben-Bassat I; Raanani P; Gale RP
Bone Marrow Transplant; 2007 Apr; 39(8):441-6. PubMed ID: 17322931
[TBL] [Abstract][Full Text] [Related]
60. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
